Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8⁺ T cell responses in mice

详细信息    查看全文

• 作者：Weibin Zhou ; PhD^a ; ¹ ; Albanus O. Moguche^b ; ¹ ; David Chiu^a ; ^c ; Kaja Murali-Krishna ; PhD^b ; ² ; Franç ; ois Baneyx ; PhD^a ; ^c ; ^{baneyx@uw.edu" class="auth_mail}
• 关键词：Nanovaccine ; Nanocarrier ; Biomineralization ; Solid binding peptide
• 刊名：Nanomedicine: Nanotechnology, Biology and Medicine
• 出版年：April, 2014
• 年：2014
• 卷：10
• 期：3
• 页码：571-578
• 全文大小：1385 K

文摘

Distributed and on-demand vaccine production could be game-changing for infectious disease treatment in the developing world by providing new therapeutic opportunities and breaking the refrigeration 鈥渃old chain鈥? Here, we show that a fusion protein between a calcium phosphate binding domain and the model antigen ovalbumin can mineralize a biocompatible adjuvant in a single step. The resulting 50 nm calcium phosphate core-immunogen shell particles are comparable to soluble protein in inducing ovalbumin-specific antibody response and class switch recombination in mice. However, single dose vaccination with nanoparticles leads to higher expansion of ovalbumin-specific CD8⁺ T cells upon challenge with an influenza virus bearing the ovalbumin-derived SIINFEKL peptide, and these cells produce high levels of IFN-纬. Furthermore, mice exhibit a robust antigen-specific CD8⁺ T cell recall response when challenged with virus 8 months post-immunization. These results underscore the promise of immunogen-controlled adjuvant mineralization for just-in-time manufacturing of effective T cell vaccines.

From the Clinical Editor

This paper reports that a fusion protein between a calcium phosphate binding domain and the model antigen ovalbumin can mineralize into a biocompatible adjuvant in a single step, enabling distributed and on-demand vaccine production and eliminating the need for refrigeration of vaccines. The findings highlight the possibility of immunogen-controlled adjuvant mineralization for just-in-time manufacturing of effective T cell vaccines.